Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...
Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...
ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...
Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...
Scientists used positron emission tomography (PET) with edaravone, a drug used to treat ALS, to detect oxidative stress, which leads to brain damage, offering a clear path to detecting neurological ...
Scientists at St. Jude Children’s Research Hospital have used positron emission tomography (PET) with edaravone, a drug used ...
Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...
News Medical on MSN6d
St. Jude researchers improve brain disease diagnosis with PET imaging and ALS drugPositron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative advance from scientists at St. Jude Children's Research Hospital is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback